Misty Anderson, DO
Internal Medicine · Valley City, NDNPI 1417109760
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Amgen at 30.2% of the total. Reporting peaked in 2019 at $546 and has fallen 89.0% since, to $60 in 2025.
Across 43 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$244
- Boehringer Ingelheim$143
- AbbVie$85
- Merck$73
- Novo Nordisk$70
- Nevro Corp.$53
- plus $141 from 7 others
What the payments were for
- Food & beverage$80299%
- Education$71%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 11 | $244 |
| Boehringer Ingelheim | 13 | $143 |
| AbbVie | 3 | $85 |
| Merck | 4 | $73 |
| Novo Nordisk | 2 | $70 |
| Nevro Corp. | 1 | $53 |
| Johnson & Johnson | 2 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $13 |
| Lilly USA, LLC | 1 | $11 |
| Novartis | 1 | $11 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$809 in reported general payments places this provider in the 80th percentile of 159 internal medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 361 | $230,022 |
| OzempicSemaglutide | 183 | $210,272 |
| JardianceEmpagliflozin | 153 | $86,710 |
| TrulicityDulaglutide | 67 | $83,484 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $58,398 |
| XareltoRivaroxaban | 89 | $56,383 |
| MounjaroTirzepatide | 29 | $31,150 |
| JanuviaSitagliptin Phosphate | 79 | $29,323 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 21 | $26,837 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $26,589 |
| FarxigaDapagliflozin Propanediol | 21 | $24,914 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $21,607 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $20,638 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $19,972 |
| Spiriva HandihalerTiotropium Bromide | 33 | $18,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $70 | $237,109204 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $11 | $114,63596 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $143 | $92,352165 claims |
| Johnson & JohnsonXarelto | $51 | $56,38389 claims |
| MerckJanuvia, Janumet | $73 | $38,605100 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $25 | $20,63816 claims |
| NovartisEntresto | $11 | $16,30625 claims |
| AbbVieLinzess | $85 | $12,05614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 159 internal medicine providers in North Dakota.
Other internal medicine in Valley City
- Michael LillestolFargo$18K
- Khalin DendyBismarck$10K
- Bruce OlinDickinson$8K
- Gene SchwartzTrenton$6K
- Stephanie CanhamBismarck$4K
- Radu RautaBismarck$3K
- Donald GrenzBismarck$3K
- Julia SchwartzBismarck$3K
- Amanda BlanchardBismarck$3K
- Brent HellaFargo$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.